Sanford Guide ID Update features current developments in infectious diseases, curated by the Sanford Guide Editorial Board. Links marked with an asterisk (*) provide details to Web Edition subscribers, while all other links are universal. If you received this message from a colleague, subscribe now.
New or Updated Treatment Guidelines
- Updated guidelines for the diagnosis (Pediatr Infect Dis J 2019;38(12S Suppl):S3), treatment (Pediatr Infect Dis J 2019;38(12S Suppl):S10), and prevention (Pediatr Infect Dis J 2019;38(12S Suppl):S22) of acute otitis media, from the Italian Society of Pediatrics. These guidelines update the 2010 release and are all available on the journal website.
- Updated HHS panel Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV. The guidelines are available on the AIDSinfo website.
- Updated HHS Recommendations for the Use of Antiretroviral Drugs in Pregnant Women with HIV Infection and Interventions to Reduce Perinatal HIV Transmission in the US. The guidelines are available on the AIDSinfo website.
- Prevention and Treatment of Cancer-Related Infections, version 1.2020, from the National Comprehensive Cancer Network (NCCN). The guidelines are available on the NCCN website.
- Revised recommendations for the use of anthrax vaccine in the United States, from the CDC Advisory Committee on Immunization Practices (MMWR Recomm Rep 2019;68(RR-4):1-14). These recommendations update the 2009 release and are available on the CDC website.
Drug Shortages (US)
- Antimicrobial drugs or vaccines in reduced supply or unavailable (as of January 5, 2020) due to increased demand, manufacturing delays, product discontinuation by a specific manufacturer, or unspecified reasons:
- [New on the list since December 9]: Neomycin and Polymyxin B sulfates GU irrigant
- [Shortage recently resolved]: Letermovir injection, Rabies immune globulin, Rabies vaccine
- [Continue to be in reduced supply]
- Aminoglycosides: Amikacin injection, Gentamicin ophthalmic ointment (unavailable), Tobramycin injection
- Carbapenems: Meropenem injection
- Cephalosporins: Cefazolin injection, Cefepime injection, Cefotaxime injection (unavailable), Cefoxitin injection, Ceftazidime injection, Cefuroxime injection
- Clindamycin injection
- Fluoroquinolones: Ciprofloxacin 0.3% ophthalmic solution, Gemifloxacin tablets
- Glycopeptides, glycolipopeptides, lipopeptides: Daptomycin injection, Vancomycin injection
- Macrolides/azalides: Azithromycin injection, Azithromycin ophthalmic solution 1% (unavailable), Erythromycin lactobionate injection
- Nitrofurantoin oral suspension
- Nitroimidazoles: Metronidazole injection
- Penicillins: Ampicillin/sulbactam injection, Piperacillin/tazobactam injection
- Tetracyclines: Doxycycline hyclate injection
- Topical (miscellaneous) antibacterials: Bacitracin ophthalmic ointment, Mupirocin calcium 2% cream, Mupirocin calcium 2% nasal ointment (unavailable), Sulfacetamide 10%/Prednisolone 0.2% ophthalmic ointment, Sulfanilamide 15% vaginal cream (unavailable)
- Antifungal drugs: Clotrimazole 10 mg oral troches, Fluconazole injection, Griseofulvin oral tablets and suspension
- Antiparasitic drugs: Pentamidine isethionate
- Antiretroviral drugs: None
- Antiviral drugs: Acyclovir injection, Cidofovir injection
- Vaccines: Hepatitis B vaccine recombinant, Zoster vaccine recombinant (Shingrix), Yellow Fever vaccine (YF-VAX is unavailable, but Stamaril can be obtained through a limited number of clinics in the US. Click here).
- Antimicrobial drugs newly discontinued:
- Recent discontinuations: Interferon alfa-2b (Intron A, in October 2019), Quinidine gluconate IV (in December 2017), Terbinafine granules (in May 2017), MenHibrix (in February 2017), Elvitegravir (Vitekta, in December 2016), Peginterferon alfa-2b (in February 2016; 50 mcg vials still available in limited quantities), Boceprevir (in December 2015), Permethrin 1% topical lotion (in September 2015).
- For detailed information including estimated resupply dates, see https://www.ashp.org/Drug-Shortages/